Your browser doesn't support javascript.
loading
Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies.
Diaz-Galvan, Patricia; Przybelski, Scott A; Algeciras-Schimnich, Alicia; Figdore, Dan J; Lesnick, Timothy G; Schwarz, Christopher G; Senjem, Matthew L; Gunter, Jeffrey L; Jack, Clifford R; Min, Paul H; Jain, Manoj K; Miyagawa, Toji; Forsberg, Leah K; Fields, Julie A; Savica, Rodolfo; Graff-Radford, Jonathan; Ramanan, Vijay K; Jones, David T; Botha, Hugo; St Louis, Erik K; Knopman, David S; Graff-Radford, Neill R; Ferman, Tanis J; Petersen, Ronald C; Lowe, Val J; Boeve, Bradley F; Kantarci, Kejal.
Afiliação
  • Diaz-Galvan P; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Przybelski SA; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
  • Algeciras-Schimnich A; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Figdore DJ; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Lesnick TG; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
  • Schwarz CG; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Senjem ML; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Gunter JL; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Jack CR; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Min PH; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Jain MK; Department of Radiology, Mayo Clinic, Jacksonville, Florida, USA.
  • Miyagawa T; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Forsberg LK; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Fields JA; Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.
  • Savica R; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Graff-Radford J; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Ramanan VK; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Jones DT; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Botha H; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • St Louis EK; Mayo Center for Sleep Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Knopman DS; Departments of Neurology and Clinical and Translational Research, Mayo Clinic Southwest Wisconsin, La Crosse, Wisconsin, USA.
  • Graff-Radford NR; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Ferman TJ; Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
  • Petersen RC; Department of Psychiatry & Psychology, Mayo Clinic, Jacksonville, Florida, USA.
  • Lowe VJ; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
  • Boeve BF; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Kantarci K; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Alzheimers Dement ; 20(4): 2485-2496, 2024 04.
Article em En | MEDLINE | ID: mdl-38329197
ABSTRACT

INTRODUCTION:

Patients with dementia with Lewy bodies (DLB) may have Alzheimers disease (AD) pathology that can be detected by plasma biomarkers. Our objective was to evaluate plasma biomarkers of AD and their association with positron emission tomography (PET) biomarkers of amyloid and tau deposition in the continuum of DLB, starting from prodromal stages of the disease.

METHODS:

The cohort included patients with isolated rapid eye movement (REM) sleep behavior disorder (iRBD), mild cognitive impairment with Lewy bodies (MCI-LB), or DLB, with a concurrent blood draw and PET scans.

RESULTS:

Abnormal levels of plasma glial fibrillary acidic protein (GFAP) were found at the prodromal stage of MCI-LB in association with increased amyloid PET. Abnormal levels of plasma phosphorylated tau (p-tau)-181 and neurofilament light (NfL) were found at the DLB stage. Plasma p-tau-181 showed the highest accuracy in detecting abnormal amyloid and tau PET in patients with DLB.

DISCUSSION:

The range of AD co-pathology can be detected with plasma biomarkers in the DLB continuum, particularly with plasma p-tau-181 and GFAP.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença por Corpos de Lewy / Transtorno do Comportamento do Sono REM / Doença de Alzheimer / Disfunção Cognitiva Limite: Humans Idioma: En Revista: Alzheimers Dement Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença por Corpos de Lewy / Transtorno do Comportamento do Sono REM / Doença de Alzheimer / Disfunção Cognitiva Limite: Humans Idioma: En Revista: Alzheimers Dement Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos